Comparable stake leader
ARMISTICE CAPITAL, LLC
SEC ownership of Kairos Pharma, LTD.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001962011.
Disclosed value leader
John S. Yu
Comparable rows
19/19
Latest evidence
31 Mar 2026
- Public ticker
- KAPA on NYSE
- Parsed ownership sources
- 13D/G, 3/4/5, and 13F
- Largest SEC-reported holder
- ARMISTICE CAPITAL, LLC
- Latest 13D/G holder
- ARMISTICE CAPITAL, LLC
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001962011
- Issuer location
- Los Angeles, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Kairos Pharma, LTD. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
John S. Yu
Comparable rows
19/19
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 5%
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-8 of 19 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
19 of 19 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
5%
John S. Yu
31%
Neil Bhowmick
7.4%
Ramachandran Murali
1.7%
Doug Samuelson
1.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 19 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$628,306
884,938 shares
|
-$576,510 | 30 Jun 2025 |
| John S. Yu |
3/4/5
CEO and Chairman, Director, 10%+ Owner
|
31%
|
$6,101,344
5,546,677 shares
|
— | 08 Oct 2025 |
| Neil Bhowmick |
3/4/5
Chief Scientific Officer
|
7.4%
|
$931,334
1,311,739 shares
|
— | 08 Oct 2025 |
| Ramachandran Murali |
3/4/5
VP of Research and Development
|
1.7%
|
$329,481
299,529 shares
|
— | 08 Oct 2025 |
| Doug Samuelson |
3/4/5
Chief Financial Officer
|
1.7%
|
$322,342
293,039 shares
|
— | 08 Oct 2025 |
| Hyun W. Bae |
3/4/5
Director
|
0.41%
|
$52,092
73,370 shares
|
— | 16 Sep 2025 |
| Rahul Singhvi |
3/4/5
Director
|
0.28%
|
$54,124
49,204 shares
|
— | 08 Oct 2025 |
| Hansoo Michael Keyoung |
3/4/5
Director
|
0.16%
|
$31,992
29,084 shares
|
— | 16 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 07 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-8 of 8 reporting-owner rows connected to Kairos Pharma, LTD.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
8
Largest Forms 3/4/5 holder
John S. Yu
Net 12M change
$0
Latest report
08 Oct 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| John S. Yu | CEO and Chairman, Director, 10%+ Owner | $6,101,344 | Mixed | 08 Oct 2025 | ||
| Neil Bhowmick | Chief Scientific Officer | $931,334 | Mixed | 08 Oct 2025 | ||
| Ramachandran Murali | VP of Research and Development | $329,481 | Mixed | 08 Oct 2025 | ||
| Doug Samuelson | Chief Financial Officer | $322,342 | Mixed | 08 Oct 2025 | ||
| Rahul Singhvi | Director | $54,124 | Mixed | 08 Oct 2025 | ||
| Hyun W. Bae | Director | $52,092 | Mixed | 16 Sep 2025 | ||
| Hansoo Michael Keyoung | Director | $31,992 | Mixed | 16 Sep 2025 | ||
| Rosemary Mazanet | Director | Mixed | 16 Sep 2024 |
Recent insider transactions for Kairos Pharma, LTD.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Neil Bhowmick | KAPA | COMMON STOCK | Award | 15.1% | 171,756 | 1,311,739 | 08 Oct 2025 | Direct | ||
| Hyun W. Bae | KAPA | COMMON STOCK | Award | 35.2% | 19,084 | 73,370 | 08 Oct 2025 | Direct | ||
| Ramachandran Murali | KAPA | COMMON STOCK | Award | 104% | 152,672 | 299,529 | 08 Oct 2025 | Direct | ||
| Hansoo Michael Keyoung | KAPA | COMMON STOCK | Award | 190.8% | 19,084 | 29,084 | 08 Oct 2025 | Direct | ||
| Rahul Singhvi | KAPA | COMMON STOCK | Award | 63.4% | 19,084 | 49,204 | 08 Oct 2025 | Direct | ||
| Doug Samuelson | KAPA | COMMON STOCK | Award | 108.8% | 152,672 | 293,039 | 08 Oct 2025 | Direct | ||
| John S. Yu | KAPA | COMMON STOCK | Award | 486% | 190,840 | 230,105 | 08 Oct 2025 | Direct | ||
| Hyun W. Bae | KAPA | COMMON STOCK | Award | 22.6% | 10,000 | 54,286 | 16 Sep 2025 | Direct | ||
| Hansoo Michael Keyoung | KAPA | COMMON STOCK | Award | 10,000 | 10,000 | 16 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.